Effect of treatment by OCP on infertility in PCOD patients
Phase 3
Recruiting
- Conditions
- Patients with hyper androgenic polycystic ovarian disease.N97.0Female inf
- Registration Number
- IRCT20140818018842N17
- Lead Sponsor
- Deputy of Research and Technology, Tehran University of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
Oligo ovulation or anovulation.
Clinical and/or biochemical signs of hyper- androgenism.
Polycystic ovaries.
Exclusion Criteria
Patients with hyper- anderogenism caused by hormonal drugs or other medications.
Patients who have known sever organ dysfunction or mental illness.
Pregnant women or being in Post- miscarriage period.
breastfeeding.
being in the 6 week postpartum period.
Patients had congenital adrenal hyperplasia or were suspected of having Cushing s syndrome or an androgen – screening neoplasm.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endometrium thickness. Timepoint: Before starting treatment and embryo transfer. Method of measurement: Trans vaginal ultra-sonography.;The number of positive chemical pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: Laboratory test (BHCG over than 40 IU).;The number of successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Trans vaginal ultrasonography.;Miscarriage rate. Timepoint: Abortion before 12 weeks of pregnancy. Method of measurement: Fetal death before 12 weeks in ultrasonography.
- Secondary Outcome Measures
Name Time Method ive birth rate. Timepoint: At 28th week of pregnancy. Method of measurement: Trans abdominal ultrasonography.